All In Biotech

Drug Trial Radar · NCT06378866

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

MC230502 Dynamic Investigator Initiated Enterprise (DIVINE) in Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 532 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

532

Planned (sponsor's estimate)

Start

Jun 3, 2024

Primary completion

Feb 28, 2031

Study completion Feb 28, 2031

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Apr 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies the effects of stereotactic body radiation therapy (SBRT) and the timing of treatment with androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT) in treating patients with hormone sensitive prostate cancer that has spread from where it first started to other places in the body (metastatic), and that has come back after a period of improvement (recurrent). It also studies the effects of salvage radiation therapy (sXRT) on prostate cancer and to see if radiation to the pelvis helps prevent prostate cancer from spreading elsewhere. SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Androgen can cause the growth of prostate cells. ADT lowers the amount of androgen made by the body. This may help stop the growth of tumor cells that need androgen to grow. Androgen receptor pathway inhibitors work by blocking the effects of androgen to stop the growth and spread of tumor cells. sXRT is a targeted radiation treatment for the prostate, typically given when cancer possibly returns after surgery or radiation. Its goal is to destroy any tumor cells in the area. Giving SBRT alone with watchful waiting may be as effective in treating prostate cancer as giving SBRT together with ARPI and ADT and sXRT may be effective in treating prostate cancer and preventing it from spreading elsewhere.

Conditions

  • Recurrent Castration-Sensitive Prostate Carcinoma
  • Recurrent Prostate Cancer
  • Castration-resistant Prostate Cancer
  • Biochemically Recurrent Prostate Carcinoma

Interventions

  • AbirateroneDrug

    Given abiraterone

  • ApalutamideDrug

    Given apalutamide

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Bone ScanProcedure

    Undergo bone scan

  • Computed TomographyProcedure

    Undergo CT

  • DarolutamideDrug

    Given darolutamide

  • DegarelixDrug

    Given degarelix

  • EnzalutamideDrug

    Given enzalutamide

  • GoserelinDrug

    Given goserelin

  • HistrelinDrug

    Given histrelin

  • LeuprolideDrug

    Given leuprolide

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Patient ObservationOther

    Undergo watchful waiting or initial observation

  • Positron Emission TomographyProcedure

    Undergo PET

  • PrednisoneDrug

    Given prednisone

  • Questionnaire AdministrationOther

    Ancillary studies

  • RelugolixDrug

    Given relugolix

  • Stereotactic Body Radiation TherapyRadiation

    Undergo SBRT

  • TriptorelinDrug

    Given triptorelin

  • Radiation TherapyRadiation

    Undergo sXRT

  • Image-Guided TherapyProcedure

    Undergo image-guided therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Modified radiographic progression-free survival (mrPFS) (Groups A & B)Time frame: Up to 5 years
  2. Distant progression-free survival (PFS) (Groups C & D)Time frame: Up to 5 years

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic in Arizona

    Phoenix, Arizona · Recruiting

  • Mayo Clinic in Florida

    Jacksonville, Florida · Recruiting

  • Mayo Clinic in Rochester

    Rochester, Minnesota · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.